title: Prospective evaluation of parenteral magnesium sulfate in the treatment of patients with reentrant AV supraventricular tachycardia.
abstract: This study prospectively assessed the electrophysiologic effects of parenteral magnesium sulfate administration on paroxysmal atrioventricular (AV) reentrant supraventricular tachycardia and the efficacy of magnesium to terminate these arrhythmias. Eleven normomagnesemic patients, seven with orthodromic reentrant supraventricular tachycardia that used an accessory AV pathway, and four with typical AV nodal reentry were examined. All patients had a history of sustained supraventricular tachycardia requiring pharmacologic therapy or electrical cardioversion for termination of tachycardia. After baseline electrophysiologic study, including documentation of sustained supraventricular tachycardia that was reproducibly induced, parenteral magnesium sulfate (a bolus of 0.3 mEq/kg of elemental magnesium infused over a 10-minute period followed by a maintenance infusion of 0.2 mEq/kg/hr) was administered during sustained supraventricular tachycardia. The serum magnesium concentration increased from (mean +/- standard deviation) 1.9 +/- 0.2 mg/dl to 4.0 +/- 0.6 mg/dl (p = 0.0001). Except for flushing and mild diaphoresis during infusion of the magnesium sulfate bolus, and dry heaves in one patient, there were no untoward effects or significant changes in systolic blood pressure. During administration of magnesium, the tachycardia cycle length increased from 319 +/- 39 msec to 348 +/- 43 msec (p = 0.0001). Slowing of the tachycardia occurred predominantly in the antegrade limb of the circuit at the level of the AV node with the AH interval increasing from 171 +/- 66 msec to 197 +/- 68 msec (p = 0.0001), whereas there was no significant change in the HV interval (43 +/- 3 msec to 43 +/- 4 msec, p = NS) or the VA interval (106 +/- 43 msec to 110 +/- 47 msec, p = NS) during tachycardia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Southern California School of Medicine 90033.
authors.forename: P T
authors.initials: PT
authors.lastname: Sager
authors.forename: J
authors.initials: J
authors.lastname: Widerhorn
authors.forename: R
authors.initials: R
authors.lastname: Petersen
authors.forename: C
authors.initials: C
authors.lastname: Leon
authors.forename: E
authors.initials: E
authors.lastname: Ryzen
authors.forename: R
authors.initials: R
authors.lastname: Rude
authors.forename: S H
authors.initials: SH
authors.lastname: Rahimtoola
authors.forename: A K
authors.initials: AK
authors.lastname: Bhandari
mesh_terms: D000328:Adult; D004594:Electrophysiology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008274:Magnesium / Q000097:blood; D008278:Magnesium Sulfate / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013614:Tachycardia, Paroxysmal / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D008278:Magnesium Sulfate; D008274:Magnesium